Today M-D-Y
Your First Name
* must provide value
Your Last Name
* must provide value
Are you trying to find information for yourself?
Yes
No
Please tell us about your relationship to the potential participant?
Biological Parent Adoptive Parent Step Parent Grandparent Spouse Child Aunt/Uncle Brother/Sister Other Relative Legal Guardian Foster Parent Medical Caregiver Other (non-relative) Refuse to answer Don't know
1. Male
2. Female
Date of birth
* must provide value
Today M-D-Y
View equation American Indian/Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More Than One Race Unknown / Not Reported
Hispanic or Latino NOT Hispanic or Latino Unknown / Not Reported Hispanic or Latino
NOT Hispanic or Latino
Unknown / Not Reported
Include Area Code
Include Area Code
Include Area Code
It seems you have forgotten to provide us with a way to contact you. Would you be kind enough to provide us with a valid phone number or an email address?
How would you like us to reach out to you?
1. Home Phone
2. Mobile Phone
3. Business Phone
4. Email
5. Any of the above
1. Home Phone
2. Mobile Phone
3. Business Phone
4. Email
5. Any of the above
It seems you have forgotten to provide us with your home phone number. Would you be kind enough to provide it so we can contact you
It seems you have forgotten to provide us with your mobile number. Would you be kind enough to provide it so we can contact you
It seems you have forgotten to provide us with your work number. Would you be kind enough to provide it so we can contact you
It seems you have forgotten to provide us with your email address. Would you be kind enough to provide it so we can contact you
What would be a good day of the week for us to contact you?
What would be a good time to contact you?
Now H:M
Has the applicant previously been diagnosed with Alzheimer's disease or another memory disorder?
Yes
No
Is the applicant interested in:
Alzheimer's Disease Research Center (ADRC) Investigator: Thomas Wisniewski, MD
Since 1973, the ADRC has been at the forefront of research on memory problems attributed to normal aging, and a pioneer in the diagnosis, causes and treatment of Alzheimer's disease. Funded by the National Institutes of Health (NIH), the NYU ADRC has contributed many significant findings that help clinicians, research scientists, and older adults and their families gain a better understanding of the causes and treatments of Alzheimer's disease.
The goal of this study is to research normal brain aging process and to improve the clinical diagnosis and treatment of Alzheimer's disease. Participants must be at least 65 years old and in good general health. Annual visits consist of a neurological exam, memory tests and blood analysis. Neuroimaging scans take place every two years. Participants receive overall feedback from each annual evaluation and a small stipend.
Yes
No
Brain Fog Biomarkers Following SARS-COV-2 Infection Investigator: Thomas Wisniewski, MD
The purpose of this study is to examine whether or not individuals who were previously diagnosed with SARS-CoV-2, or COVID-19, have greater cognitive and biomarker changes over five years than those individuals who did not have COVID-19.
Yes
No
A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients with Early Alzheimer's Disease (AD) with a Stage Gate to Phase 2B (VIVA-MIND) Investigator: Arjun Masurkar, MD
VIVA-MIND is a research study evaluating an investigational drug called varoglutamstat (PQ912) in those with early Alzheimer's disease (AD) to determine the best dose and see if it helps symptoms and long-term progression of AD. You may receive the investigational drug or a placebo in the trial. A placebo looks like the study drug but does not have active medication. Participants must be 50-89 years with mild memory problems due to AD or mild probable AD.
Yes
No
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia (Biogen 247AD201 CELIA) Investigator: Martin Sadowski, MD, PhD
The purpose of this study is to test the safety, effectiveness, and tolerability of an investigational drug called BIIB080. This trial would include 735 participants that would be given either the study drug or the placebo. A placebo looks like the study drug but does not have active medication. Participants must be 50-80 years of age and have a clinical diagnosis of memory problems due to Alzheimer's disease (AD) or mild AD dementia.
Yes
No
A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab in Participants with Alzheimer's Disease (Biogen 221AD305 ENVISION) Investigator: Martin Sadowski, MD, PhD
This research study aims to determine whether aducanumab (ADUHELM) can slow done the progression of Alzheimer's disease (AD) in those with early AD. Aducanumab is not an experimental drug and has accelerated approval by the United States Food and Drug Administration (FDA). Participants would be
Yes
No
Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD) Investigator: Dan Iosifescu, MD, MSc; Ricardo Osorio, MD; Paolo Cassano, MD, PhD
TRAP-AD is a research study investigating if an experimental treatment device will lead to improvement in cognition in adults with amnestic Mild Cognitive Impairment (aMCI). The treatment, transcranial photobiomodulation (t-PBM), uses near-infrared light therapy to stimulate certain parts of the brain that are thought to be affected in memory impairment. Infrared energy is a form of light not visible to the human eye. Researchers hope to determine the effectiveness of t-PBM for improving cognition in adults with aMCI.
Yes
No
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) PI: Martin Sadowski, MD, PhD
The Alzheimer's Disease Neuroimaging Initiative, also known as ADNI, is a historic study of brain aging looking to help change the future. ADNI's unprecedented approach to research is intended to encourage new investigation and to increase the pace of discovery in the race to prevent, treat, and one day cure Alzheimer's disease.
ADNI is seeking people over age 55 who are healthy, as well as those with mild memory problems and those who have been diagnosed with mild dementia due to Alzheimer's. There is no experimental medication involved.
Yes
No
Improving Oral Health for Persons with Mild Dementia Investigator: Bei Wu, PhD
Good oral health promotes good general health, and poor oral health may be associated with a higher risk of cognitive decline. The Oral Health Study aims to improve oral health and reduce risk of oral health problems in people with memory problems and can help educate caregivers how to help their loved one. Participants receive 3 in-home visits by an Oral Health Evaluator, learn about oral health, and receive financial compensation. The study is seeking people diagnosed with mild dementia who live with a caregiver. Participants must be age 60 with at least 4 natural teeth and be able to brush their own teeth.
Yes
No
Resolvant Investigator: Omonigho M. Bubu, MD, MPH, PhD
This research study is being done to collect information about sleep as a potential risk factor that may increase Alzheimer's disease burden particularly in African-Americans. We will do this through an in-lab sleep study and one Tau PET-MR scan of your brain that requires the injection of small amounts of a radioactive PI2620 tracer or MK-6240 tracer. This is an investigational tracer. This means it hasn't been approved by the US Food and Drug Administration (FDA) for use outside of studies like this. More information about this scan will be provided later in the consent form. Tau is one of the brain markers or lesions that can be found in the brain of Alzheimer's disease. We hope to identify the mechanisms by which age-related sleep changes contribute to brain loss in Alzheimer's Disease in normal elderly patients.
Yes
No
Sleep AWARE Investigator: Ricardo Osorio, MD
Sleep AWARE is a research study funded by the National Institutes of Health and the National Institutes for Aging. We will examine how race, genes, and other factors impact an individual's risk for developing Alzheimer's disease (AD). Poor sleep is thought to contribute to increased risk for developing AD. African Americans in particular have lower quality sleep and less sleep duration and thus may be at greater risk for AD. Researchers hope to compare sleep characteristics and their effects on Alzheimer's disease risk among African Americans and non-Hispanic Whites.
Yes
No
Understanding CSF Clearance in Normal Aging and Alzheimer's Brains Through Dynamic Sodium MRI Investigator: Yongxian Qian, PhD
Cerebrospinal fluid (CSF) plays a major role in cleaning waste proteins (including amyloid-beta) from the brain. Efficiency of CSF clearance may decrease with age, leading to accumulation of amyloid-beta and formation of the plagues that are toxic to neurons and interrupt communication between them. We use state-of-the-art sodium MRI technologies to non-invasively measure dynamics of the CSF flow inside the brain, and quantify its changes with aging, its difference between normal and AD patients, and its alterations during sleep. This study is funded by the National Institute on Aging (NIA) of the National Institutes of Health (NIH). People at age 25-120 years (either in normal cognition or already diagnosed as early AD) are encouraged to participate in the study as volunteers for two sessions of MRI scans (i.e., 1.0 hour MRI in the morning and 1.5 hours MRI in the afternoon for sleep monitored by EEG), with no injection of contrast materials.
Yes
No
In Vivo Insights of Small Vessel Changes with Age Using Ultra-Small-Superparamagnetic-Iron-Oxide (USPIO)-Enhanced MRI Investigator: Yulin Ge, MD
This proposal seeks to perform an observational study for developing a new imaging tool using an ultra-small-superparamagnetic-iron-oxide (USPIO) contrast agent. The objective is to characterize age-related microvascular changes on both 3T and 7T MRI and better understand the source and basis of brain aging. This study will include 130 total healthy volunteers asked to undergo a single 7T contrast-enhanced MRI. You may join this study if you are healthy and aged 18-85.
Yes
No
Mechanisms of Age-Related White Matter Hyperintensities: Insights from Advanced MRI Investigator: Yulin Ge, MD
Small vessel disease (SVD) is an age-related diffuse white matter disease associated with white matter hyperintensities (WMHs) seen on brain MRI scans. SVD is a common cause of vascular cognitive impairment in the elderly. In this study, we will characterize the underlying vascular pathophysiological changes of WMHs using non-invasive and multimodal MRI measures and follow them over a period of 2.5 years in an elderly population with diverse WMH burdens. This study will include 160 participants for two visits consisting of a single 1-hour 3T MRI at each visit without administration of contrast agent. You may participate in this study if you are 65-85 years old and have a recent clinical MRI indicating you have white matter lesions present in your brain on the previous MRI.
Yes
No
A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol.
Yes
No
Intramuscular Injection (CAD106) and BACE (β-secretase) Inhibitor (CNP520) to prevent or delay onset of Alzheimer's Disease in people that are Positive for the APOE4 Gene (The Generation Study)
Yes
No
SUVN-502 as Treatment for Subject with Moderate Alzheimer's Disease currently treated with Donepezil Hydrochoride and Memantine Hydrochloride (Suven Study)This is a phase 2 research trial of an oral investigational medication called SUVN-502 that is meant to test the effect on the symptoms of moderate Alzheimer's disease when given alongside standard treatments of donepezil and Mementine (both supplied by the study). The trial is for individuals who are between the ages of 50 and 85 that have been diagnosed with Alzheimer's disease for at least a year. Participation consists of 26 weeks of "double blind" (possibility of placebo) treatment and a mandatory caregiver. Please note that participants cannot be taking any other Alzheimer's disease medication except for Donepezil (Aricept) and Mementine (Namenda) during the course of the trial.
Yes
No
Neurotrack Test ValidationDetection of Alzheimer's disease during its early (preclinical) stage has become very important for developing treatments to slow down or prevent the disease. Biomarkers, such as the Magnetic Resonance Imaging (MRI) scan for detecting the shrinkage of brain regions, have been developed to detect Alzheimer-related brain pathology, but these methods are invasive, expensive or both. This study will validate new computer memory and thinking tests (known as cognitive tasks) that may detect memory problems in the preclinical stage of Alzheimer's when there are no symptoms. Participants will perform the cognitive tasks and receive an MRI scan. Performance on the cognitive tasks will be compared to the scan results to discover if the tests can evaluate people at risk for developing Alzheimer's. You may join this study if you are between the ages of 60 to 85, inclusive and are in general good health.
Yes
No
Long-Term Nicotine Treatment of Mild Cognitive Impairment (MIND)The Memory Improvement Through Nicotine Dosing (MIND) study will determine whether daily transdermal nicotine will have a positive effect on early memory loss in people diagnosed with MCI. We need your help. If you are a healthy, non-smoking adult age 55+ and are interested in learning more about this study. There is no cost to participate.
Yes
No
A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (Generation 2)
Yes
No
Anti-viral Therapy in Alzheimer's DiseaseAnti-viral therapy in Alzheimer's disease will investigate the efficacy of treating patients with mild Alzheimer's disease with the U.S.A marketed generic anti-viral drug Valtrex (VALAD)
Yes
No
Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label TreatmentThe purpose of this study is to determine the safety and efficacy of TRx0237 16 mg/day and 8 mg/day in the treatment of subjects with Alzheimer's Disease compared to placebo (TauRx).
Yes
No
A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease (Clarity AD)This study will be conducted to evaluate the efficacy of BAN2401 in participants with early Alzheimer's disease (EAD) by determining the superiority of BAN2401 compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This study will also evaluate the long-term safety and tolerability of BAN2401 in participants with EAD in the Extension Phase and whether the long-term effects of BAN2401 as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase. (EISAI)
Yes
No
Submit
Save & Return Later
